Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1168818 | 0.86 | USP2 (0.50) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL5749973 | 0.84 | USP2 (0.51) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL10290907 | 0.84 | USP2 (0.55) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL1692872 | 0.83 | USP2 (0.47) | USP2SMN1; SMN2HPGDEPHX2EPHX1 | |
| SCHEMBL2800312 | 0.83 | USP2 (0.47) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL346481 | 0.83 | USP2 (0.50) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL182080 | 0.82 | USP2 (0.53) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL12653430 | 0.82 | USP2 (0.44) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL6505941 | 0.82 | USP2 (0.46) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL2348214 | 0.81 | USP2 (0.49) | USP2SMN1; SMN2HPGDEPHX2RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4608839-A1 | SPIROCYCLE CONTAINING BICYCLIC HETEROARYL COMPOUNDS | Protego Biopharma, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20240174695-A1 | Spirocycle Containing Bicyclic Heteroaryl Compounds | PROTEGO BIOPHARMA, INC. | 2024-05-30 | — | — | US | disclosed |
| US-20240174611-A1 | SUBSTITUTED CYCLIC MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | RAPPTA THERAPEUTICS OY (FI) | 2024-05-30 | — | — | US | disclosed |
| WO-2024092040-A1 | SPIROCYCLE CONTAINING BICYCLIC HETEROARYL COMPOUNDS | PROTEGO BIOPHARMA, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| US-11932643-B2 | Substituted heterocyclic inhibitors of PTPN11 | NAVIRE PHARMA, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| EP-4288414-A1 | SUBSTITUTED CYCLIC MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | Rappta Therapeutics Oy (FI) | 2023-12-13 | — | — | EP | disclosed |
| US-11840536-B2 | Heterocyclic inhibitors of PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-12-12 | — | — | US | disclosed |
| CN-112351780-B | Substituted heterocyclic inhibitors of PTPN11 | 纳维尔制药有限公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-116806217-A | Substituted cyclic modulators of protein phosphatase 2A (PP 2A) and methods of use thereof | 拉帕塔疗法公司 | 2023-09-26 | — | — | CN | disclosed |
| US-20230109858-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-04-13 | — | — | US | disclosed |
| US-20090253725-A1 | ACETYL CoA CARBOXYLASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-08 | — | — | US | disclosed |
| US-20090253725-A1 | ACETYL CoA CARBOXYLASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-08 | — | — | US | disclosed |
| US-20090176769-A1 | CGRP RECEPTOR ANTAGONISTS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| WO-2009020470-A2 | CGRP RECEPTOR ANTAGONISTS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-12 | — | — | WO | disclosed |
| US-20080070899-A1 | Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2008-03-20 | — | — | US | disclosed |
| US-20080070899-A1 | Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2008-03-20 | — | — | US | disclosed |
| US-20080004261-A1 | CGRP receptor antagonists | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-03 | — | — | US | disclosed |
| US-20080004261-A1 | CGRP receptor antagonists | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-03 | — | — | US | disclosed |
| WO-2007146349-A2 | CGRP RECEPTOR ANTAGONISTS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-21 | — | — | WO | disclosed |
| CN-101072771-A | Cgrp receptor antagonists | MERCK & CO INC (US) | 2007-11-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176769-A1 | CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, GRPR | USP2 3304/4885SMN1; SMN2 3467/4885HPGD 554/4885 |
| US-20080070899-A1 | Cgrp Receptor Antagonists | BDKRB1, CCKBR, CALCRL | USP2 3885/4885SMN1; SMN2 4711/4885HPGD 880/4885 |
| US-20230109858-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | PTPRJ, PTPN11, PTPRCAP | USP2 1045/4885SMN1; SMN2 4183/4885HPGD 1782/4885 |
| US-20090253725-A1 | ACETYL CoA CARBOXYLASE INHIBITORS | ACACA, ACACB, ACAT1 | USP2 512/4885SMN1; SMN2 4390/4885HPGD 1103/4885 |
| US-20240174695-A1 | Spirocycle Containing Bicyclic Heteroaryl Compounds | BCL6, BCL6B, BCL9 | USP2 4207/4885SMN1; SMN2 672/4885HPGD 1853/4885 |
| US-11932643-B2 | Substituted heterocyclic inhibitors of PTPN11 | PTPN11, PTPRJ, PTPRCAP | USP2 1009/4885SMN1; SMN2 4080/4885HPGD 1873/4885 |
| US-20080004261-A1 | CGRP receptor antagonists | CALCRL, CALCR, GRPR | USP2 3304/4885SMN1; SMN2 3467/4885HPGD 554/4885 |
| US-20240174611-A1 | SUBSTITUTED CYCLIC MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | PPP2CA, PPP3CA, PPP4C | USP2 406/4885SMN1; SMN2 2512/4885HPGD 2816/4885 |
| US-11840536-B2 | Heterocyclic inhibitors of PTPN11 | PTPRJ, PTPN11, PTPRCAP | USP2 1045/4885SMN1; SMN2 4183/4885HPGD 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.